• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

  • Print
  • Share
  • E-mail
-

Patent and Exclusivity Search Results from query on Appl No 022511 Product 002 in the OB_Rx list.


Patent Data

Appl No Prod No Patent No Patent
Expiration
Drug Substance
Claim
Drug Product
Claim
Patent Use
Code
Delist
Requested
N022511 002 5714504 Feb 3, 2015 Y U - 1053
N022511 002 5714504*PED Aug 3, 2015
N022511 002 5900424 May 4, 2016 Y U - 1053
N022511 002 5900424*PED Nov 4, 2016
N022511 002 6369085 May 25, 2018 Y Y U - 1053
N022511 002 6369085*PED Nov 25, 2018
N022511 002 6875872 May 27, 2014 Y
N022511 002 6875872*PED Nov 27, 2014
N022511 002 6926907 Feb 28, 2023 Y U - 1052
N022511 002 7411070 May 25, 2018 Y U - 1053
N022511 002 7411070*PED Nov 25, 2018
N022511 002 7745466 Oct 13, 2018 Y U - 1053
N022511 002 8557285 May 31, 2022 Y

Exclusivity Data

There is no unexpired exclusivity for this product.


Additional information:

  1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
  2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.


View a list of all patent use codes
View a list of all exclusivity codes

Return to Electronic Orange Book Home Page


FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Division of Labeling and Program Support
Update Frequency:

Orange Book Data - Monthly
Generic Drug Product Information & Patent Information - Daily
Orange Book Data Updated Through September 2014
Patent and Generic Drug Product Data Last Updated October 22, 2014

-
-